Advice
following a re-submission
olodaterol (Striverdi® Respimat®) is accepted for use within NHS Scotland.
Indication under review: maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.
In two 48-week studies there was no significant difference between olodaterol 5 microgram and another long acting beta2 agonist for the primary endpoints of trough forced expiratory volume in 1 second (FEV1) and FEV1 area under curve (0 to 3 hours) at week 24.
Download detailed advice190KB (PDF)
Medicine details
- Medicine name:
- olodaterol respimat (Striverdi Respimat)
- SMC ID:
- 974/14
- Indication:
- Maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 12 January 2015